Coherus Biosciences to Buy Surface Oncology for US$65 M
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 6 (Table of Contents)
Published: 28 Jun-2023
DOI: 10.3833/pdr.v2023.i6.2794 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Expanding beyond its biosimilars business, Coherus Biosciences has agreed to acquire Surface Oncology, a clinical stage immuno-oncology company, in a transaction worth up to US$65 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS